All In Biotech

Drug Trial Radar · NCT00086684

Effectiveness and Safety Study of Pentosan Polysulfate Sodium for the Treatment of Interstitial Cystitis

Randomized, Double-Blind, Placebo-Controlled, Parallel Group Evaluation of the Efficacy and Tolerability of Two Different Doses of ELMIRON for the Treatment of Interstitial Cystitis

Last checked: Nov 19, 2026Latest source record: Apr 21, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingRandomized with 369 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

369

Actual

Start

Sep 2003

Primary completion

Jun 2011

Study completion Jun 2011

Sponsor

Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Johnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Jul 9, 2004

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety and effectiveness of pentosan polysulfate sodium 100 mg once a day, pentosan polysulfate sodium 100 mg three times a day, and placebo for 24 weeks for the relief of bladder pain or discomfort associated with interstitial cystitis.

Conditions

  • Interstitial Cystitis

Interventions

  • Pentosan polysulfate sodium 100 mgDrug

    One 100 mg pentosan polysulfate sodium capsule 3 times a day (morning, afternoon, and evening) for 24 weeks

  • PlaceboDrug

    One placebo capsule 3 times a day (morning, afternoon and evening) for 24 weeks

  • Pentosan polysulfate sodium 100 mgDrug

    One 100 mg pentosan polysulfate sodium capsule in the morning, and 1 matching placebo capsule in the afternoon and evening for 24 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Responders Defined as Having at Least a 30% Reduction in the O'Leary-Sant Interstitial Cystitis Symptom Index (ICSI) From Baseline to Study EndpointTime frame: Baseline to Week 24

Locations

65 sites in 2 countries. Site status is shown where the registry gives one.

  • Site not named

    Birmingham, Alabama

  • Site not named

    Homewood, Alabama

  • Site not named

    Anchorage, Alaska

  • Site not named

    San Bernardino, California

  • Site not named

    San Carlos, California

  • Site not named

    San Diego, California

  • Site not named

    Torrance, California

  • Site not named

    Denver, Colorado

  • Site not named

    Longmont, Colorado

  • Site not named

    Wheat Ridge, Colorado

  • Site not named

    Newington, Connecticut

  • Site not named

    Norwalk, Connecticut

  • Site not named

    Celebration, Florida

  • Site not named

    Longwood, Florida

  • Site not named

    Plantation, Florida

  • Site not named

    Tampa, Florida

  • Site not named

    Trinity, Florida

  • Site not named

    Venice, Florida

  • Site not named

    Weston, Florida

  • Site not named

    Atlanta, Georgia

  • Site not named

    Centralia, Illinois

  • Site not named

    Evanston, Illinois

  • Site not named

    Peoria, Illinois

  • Site not named

    Jeffersonville, Indiana

  • Site not named

    Dearborn, Michigan

  • Site not named

    Grand Rapids, Michigan

  • Site not named

    Kalamazoo, Michigan

  • Site not named

    St Louis, Missouri

  • Site not named

    Henderson, Nevada

  • Site not named

    West Orange, New Jersey

  • Site not named

    Albany, New York

  • Site not named

    Charlotte, North Carolina

  • Site not named

    Concord, North Carolina

  • Site not named

    Winston-Salem, North Carolina

  • Site not named

    Lima, Ohio

  • Site not named

    Ponca City, Oklahoma

  • Site not named

    Tulsa, Oklahoma

  • Site not named

    Medford, Oregon

  • Site not named

    Portland, Oregon

  • Site not named

    Philadelphia, Pennsylvania

Showing 40 of 65 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.